18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.

[1]  M. O'Doherty,et al.  Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. , 1999, The Annals of thoracic surgery.

[2]  F Levi,et al.  The European mesothelioma epidemic , 1999, British Journal of Cancer.

[3]  J. Jett,et al.  Phase II trial of topotecan for the treatment of mesothelioma. , 1998, American journal of clinical oncology.

[4]  A. Kivisaari,et al.  The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma. , 1998, Lung cancer.

[5]  R. Rubens,et al.  Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Alavi,et al.  Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. , 1998, Chest.

[7]  James M. Wilson,et al.  Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. , 1998, Human gene therapy.

[8]  M. Hünerbein,et al.  Video-assisted thoracic surgery , 1998, Surgical Endoscopy.

[9]  N. Dewan,et al.  Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. , 1997, Chest.

[10]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[11]  S. Reske,et al.  Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). , 1997, Thorax.

[12]  A. Dowlati,et al.  Evaluation of pleural diseases with FDG-PET imaging: preliminary report. , 1997, Thorax.

[13]  J. Galbis,et al.  Videothoracoscopy in the Diagnosis and Treatment of Malignant Pleural Mesothelioma with Associated Pleural Effusions , 1997, The Thoracic and cardiovascular surgeon.

[14]  S S Gambhir,et al.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  P. Valk,et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. , 1995, The Annals of thoracic surgery.

[16]  V. Rusch.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. , 1995, Chest.

[17]  T J Dougherty,et al.  Intracavitary photodynamic therapy for malignant pleural mesothelioma. , 1995, Seminars in surgical oncology.

[18]  M. Metintaş,et al.  CT‐Guided Pleural Needle Biopsy in the Diagnosis of Malignant Mesothelioma , 1995, Journal of computer assisted tomography.

[19]  J. Douillard,et al.  Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma , 1994, Cancer.

[20]  M. Hsieh,et al.  Video-assisted thoracic surgery. The Chang Gung experience. , 1994, The Journal of thoracic and cardiovascular surgery.

[21]  V. Lowe,et al.  Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. , 1994, Radiology.

[22]  G. van Kaick,et al.  Evaluation of recurrent bronchogenic carcinoma by computed tomography. , 1990, Clinical imaging.

[23]  R R Miller,et al.  CT in differential diagnosis of diffuse pleural disease. , 1990, AJR. American journal of roentgenology.

[24]  R Spirtas,et al.  Demographic patterns for mesothelioma in the United States. , 1987, Journal of the National Cancer Institute.

[25]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  W. Richards,et al.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. , 1999, The Journal of thoracic and cardiovascular surgery.